Literature DB >> 21556836

Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Krista S Viau1, Heidi J Wengreen, Sharon L Ernst, Nancy L Cantor, Larissa V Furtado, Nicola Longo.   

Abstract

Patients with treated phenylketonuria (PKU) can have subtle deficits in intellect, academic skills, and executive functioning. This study evaluates the relationship between intellectual outcome and concentration/variation in blood phenylalanine (Phe) during specific developmental periods (0-6 years, 7-12 years, >12 years) in our patients with PKU. Verbal comprehension, perceptual reasoning, and processing speed were used as measures of intelligence. Data were collected from 55 patients receiving treatment at the University of Utah Metabolic Clinic. Yearly median Phe levels increased and mean number of blood Phe samples decreased as patients aged. Yearly median blood Phe from 0-6 and 7-12 years were inversely associated with perceptual reasoning abilities using linear regression. Additionally, increased blood Phe concentration negatively impacted specific areas of verbal comprehension abilities for those 0-6 years of age (p = 0.001). Variation of Phe levels around the mean (assessed as standard deviation) in each patient was associated with diagnostic (highest pretreatment) Phe levels and yearly median Phe levels (p < 0.001 for both), but did not significantly impact intelligence in our group of patients. Frequent blood Phe monitoring from 7-12 years significantly reduced the probability of yearly median Phe exceeding 360 μM (p = 0.005). Our data show that compliance with treatment in patients with PKU affects both the concentration and variation of blood Phe levels, and may have a greater impact on verbal comprehension and perceptual reasoning skills during the first 12 years of life when compared the influence beyond 12 years.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556836     DOI: 10.1007/s10545-011-9329-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  40 in total

1.  Comments on the neuropathology of phenylketonuria.

Authors:  C A Dyer
Journal:  Eur J Pediatr       Date:  2000-10       Impact factor: 3.183

2.  Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population.

Authors:  Rosa Gassió; Rafael Artuch; Maria Antonia Vilaseca; Eugenia Fusté; Cristina Boix; Anna Sans; Jaume Campistol
Journal:  Dev Med Child Neurol       Date:  2005-07       Impact factor: 5.449

3.  Quality of dietary control in phenylketonuric patients and its relationship with general intelligence.

Authors:  M A Vilaseca; N Lambruschini; Lilianne Gómez-López; A Gutiérrez; E Fusté; R Gassió; R Artuch; J Campistol
Journal:  Nutr Hosp       Date:  2010 Jan-Feb       Impact factor: 1.057

4.  Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

Authors:  B A Stemerdink; A F Kalverboer; J J van der Meere; M W van der Molen; J Huisman; L W de Jong; F M Slijper; P H Verkerk; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

Review 5.  ADHD, learning, and academic performance in phenylketonuria.

Authors:  Kevin M Antshel
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

Review 6.  Outcomes beyond phenylalanine: an international perspective.

Authors:  Francois Feillet; Anita MacDonald; Danielle Hartung Perron; Barbara Burton
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

7.  A neuropsychological profile of off-diet adults with phenylketonuria.

Authors:  J J Moyle; A M Fox; M Bynevelt; M Arthur; J R Burnett
Journal:  J Clin Exp Neuropsychol       Date:  2007-05       Impact factor: 2.475

8.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

9.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

View more
  14 in total

1.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

2.  Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.

Authors:  Oriane Leuret; Magalie Barth; Alice Kuster; Didier Eyer; Loïc de Parscau; Sylvie Odent; Brigitte Gilbert-Dussardier; François Feillet; François Labarthe
Journal:  J Inherit Metab Dis       Date:  2012-03-03       Impact factor: 4.982

3.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

4.  Phenylalanine Monitoring via Aptamer-Field-Effect Transistor Sensors.

Authors:  Kevin M Cheung; Kyung-Ae Yang; Nako Nakatsuka; Chuanzhen Zhao; Mao Ye; Michael E Jung; Hongyan Yang; Paul S Weiss; Milan N Stojanović; Anne M Andrews
Journal:  ACS Sens       Date:  2019-11-01       Impact factor: 7.711

5.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

6.  Molecular epidemiology, genotype-phenotype correlation and BH4 responsiveness in Spanish patients with phenylketonuria.

Authors:  Luis Aldámiz-Echevarría; Marta Llarena; María A Bueno; Jaime Dalmau; Isidro Vitoria; Ana Fernández-Marmiesse; Fernando Andrade; Javier Blasco; Carlos Alcalde; David Gil; María C García; Domingo González-Lamuño; Mónica Ruiz; María A Ruiz; Luis Peña-Quintana; David González; Felix Sánchez-Valverde; Lourdes R Desviat; Belen Pérez; María L Couce
Journal:  J Hum Genet       Date:  2016-04-28       Impact factor: 3.172

Review 7.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

8.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

9.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

10.  Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy.

Authors:  Nicola Longo; Komudi Siriwardena; Annette Feigenbaum; David Dimmock; Barbara K Burton; Sylvia Stockler; Susan Waisbren; William Lang; Elaina Jurecki; Charlie Zhang; Suyash Prasad
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.